Quality-of-Life Management for COPD Patients

Copd Clinical Trial

— CAir  

Official title:

CAir: Quality-of-Life Management for COPD Patients

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04373070
• Other study ID #: 2020-00707
• Status: Completed
• Phase: N/A
• Start date: February 3, 2021
• Est. completion date: May 30, 2022

Study information

• Verified date: November 2022
• Source: University of Zurich
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The investigators aim to investigate the effects of a telemonitoring and chatbot-based application of "Living well with COPD" (CAir) on health-related quality-of-life in patients with COPD.

Description:

The disease management programme "Living well with COPD" was developed to relieve symptoms and prevent exacerbations. It covers a disease self-management approach, educational topics, lifestyle coaching and physical activity advice. Future implications should aim to make the intervention easily accessible for a broad spectrum of patients at scalable costs. Patients need an engaging communication platform which can inform, coach and even listen in between medical visits. The inclusion of a chatbot agent may provide this tailored feedback. The investogator's aim is to investigate the effects of a telemonitoring and chatbot-based application of "Living well with COPD" on health-related quality-of-life in patients with COPD.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 35
• Est. completion date: May 30, 2022
• Est. primary completion date: May 30, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 40 Years and older

Eligibility

Inclusion Criteria:

• Diagnosed COPD according to GOLD-guidelines

Exclusion Criteria:

• Physical or intellectual impairment precluding informed consent or protocol adherence
• Non-German speaking
• Acute or recent (within the last 6 weeks) exacerbation of COPD
• Attending a pulmonary rehabilitation program within the last 3 months
• Pregnant patients

Related Conditions & MeSH terms

• Chronic Respiratory Disease
• Copd
• Respiration Disorders
• Respiratory Tract Diseases

Intervention

Combination Product:
• CAir
The CAir desk is a custom-built home disease monitoring device. The device consists of a smartphone (A320 [2017], Samsung Group, Seoul, Korea), home spirometer (Air Next Spirometer, NuvoAir, Stockholm, Sweden), physical activity tracker (Charge 3, Fitbit Inc., San Francisco CA, USA), and an air-quality monitor (Foobot, Airboxlab, Esch sur Alzette, Luxembourg). The components of the CAir desk are CE-certified.

Locations

Country	Name	City	State
Switzerland	University Hospital Zurich	Zurich

Sponsors (1)

Lead Sponsor	Collaborator
University of Zurich

Country where clinical trial is conducted

Switzerland, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Health-related quality-of-life (HrQoL)	St. George Respiratory Questionnaire (SGRQ). Scoring: Scores range from 0 to 100, with higher scores indicating more limitations.	3 months
Secondary	Symptom burden	COPD Assessment Test (CAT). Scoring: Scores range from 0-40, with higher scores indicating more symptoms.	3 months
Secondary	Spirometry	Forced expiratory volume in one second (FEV1) in liters and percent predicted.	3 months
Secondary	Spirometry	Forced vital capacity (FVC) in liters and percent predicted.	3 months
Secondary	Accelerometry	Daily step count (number of steps)	3 months
Secondary	Functional exercise capacity	Six-minute walk test (6MWT) in meters walked.	3 months
Secondary	Functional exercise capacity	One-minute sit-to-stand test (1MSTS) in repetitions performed.	3 months